Predictive Role of sTREM in Endovascular Thrombectomy Outcomes
Soluble Soluble Triggering Receptors Expressed on Myeloid Cells (sTREM) Predict Outcomes in Stroke Patients Receiving Endovascular Thrombectomy
1 other identifier
observational
300
1 country
1
Brief Summary
Soluble triggering receptor expressed on myeloid cells (sTREM), which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. This study is to investigatethe prognostic roles of sTREM (sTREM1 and sTREM2) in patients with ischemic stroke who underwent endovascular thrombectomy (EVT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2024
CompletedFirst Submitted
Initial submission to the registry
August 4, 2024
CompletedFirst Posted
Study publicly available on registry
August 9, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
August 9, 2024
August 1, 2024
3.5 years
August 4, 2024
August 7, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Dynamic changes in plasma levels of sTREM-1 and sTREM-2 following Endovascular Therapy
Plasma levels of sTREM-1 and sTREM-2 will be quantified using the ELISA method.
From baseline to immediately, 24 hours, 3 days, and 7 days after Endovascular Therapy
Secondary Outcomes (4)
favourable functional outcome, defined as modified Rankin Scale (mRS) 0-2
90 days
excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1
30 days
early neurological improvement, defined as 4 or more decrease in National Institute of Health stroke scale (NIHSS)
24 hours
Hemorrhagic transformation
72 hours
Study Arms (3)
EVT-stroke group
Patients with ischemic stroke who received endovascular thrombectomy (EVT) treatment
non--EVT stroke group
The non--EVT stroke group was composed of patients with ischemic stroke without endovascular thrombectomy (EVT) treatment during the same period
non--stroke control group
The non--stroke control group was composed of randomly selected stroke--free, age--matched and sex--matched individuals recruited from the health examination center.
Eligibility Criteria
There will be 200 patients with stroke who underwent EVT (Endovascular Therapy), 50 patients with non--EVT stroke and 50 non--stroke controls.
You may qualify if:
- Patients \> 18 years old.
- Patients with acute large vessel occlusion within 24 hours of onset who will receive endovascular treatment.
You may not qualify if:
- Impossibility of getting a blood sample.
- Impossibility of performing the test (Invalid results).
- Refusal to provide the informed consent by the patient/relative.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Neurology
Xuzhou, Jiangsu, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 4, 2024
First Posted
August 9, 2024
Study Start
July 1, 2024
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
August 9, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share